Connor, Clark & Lunn Investment Management Ltd. Arcus Biosciences, Inc. Transaction History

Connor, Clark & Lunn Investment Management Ltd.

$21.8 Billion
Q1 2024

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 05, 2022	SELL	$17.23 - $37.73 $3.67 Million - $8.03 Million	-212,743 Closed	0 $0
Q1 2022 May 12, 2022	SELL	$28.92 - $41.83 $1.56 Million - $2.25 Million	-53,800 Reduced 20.18%	212,743 $6.71 Million
Q4 2021 Feb 10, 2022	SELL	$31.38 - $48.47 $190,288 - $293,922	-6,064 Reduced 2.22%	266,543 $10.8 Million
Q3 2021 Nov 12, 2021	BUY	$26.93 - $37.68 $104,919 - $146,801	3,896 Added 1.45%	272,607 $9.51 Million
Q2 2021 Aug 12, 2021	BUY	$22.75 - $35.77 $1.13 Million - $1.77 Million	49,586 Added 22.63%	268,711 $7.38 Million

Q1 2021 May 13, 2021	BUY	$26.16 - $41.39 $643,169 - $1.02 Million	24,586 Added 12.64%	219,125 $6.15 Million
Q4 2020 Feb 16, 2021	BUY	$17.0 - $32.36 $1.84 Million - $3.51 Million	108,525 Added 126.17%	194,539 $5.05 Million
Q3 2020 Nov 12, 2020	BUY	$17.14 - $25.47 $1.47 Million - $2.19 Million	86,014 New	86,014 $1.47 Million

Others Institutions Holding RCUS

# of Institutions

186

Shares Held

49.2M

Call Options Held

204K

Put Options Held

149K

Black Rock Inc. New York, NY

9.9M
Shares

$151 Million
0.0% of portfolio
State Street Corp Boston, MA

4.9M
Shares

$74.7 Million
0.0% of portfolio
Vanguard Group Inc Valley Forge, PA

4.79M
Shares

$73 Million
0.0% of portfolio
Woodline Partners LP San Francisco, CA

2.88M
Shares

$43.9 Million
0.52% of portfolio
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct

1.91M
Shares

$29.2 Million
0.09% of portfolio

View Full List

About Arcus Biosciences, Inc.

Ticker RCUS
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 72,160,000
Market Cap $1.1B
Description
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for ...

More about RCUS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Connor, Clark & Lunn Investment Management Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Connor, Clark & Lunn Investment Management Ltd. with notifications on news.

Account